HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Competition Fuels Personalized Medicine Market, First-Line Positions Eyed for Xalkori, Alecensa

Lexicon

Japan-Version NIH Initiative:
日本版NIH構想

The Column

Taking Pride in Small Things Makes Big Things Possible

Archives

JPMA to Examine Clinical Trial Costs(Aug.01)
Improvement Order Issued to Novartis over Delayed ADR Reporting(Aug.01)
Kyowa Kirin, AstraZeneca Hook Up in Immuno-Oncology Clinical Study(Aug.01)
Kyowa Kirin Taking Nesp Issue Seriously from Ethical Standpoint: Pres.(Aug.01)
Government to Increase Review Fee for New Generic Drugs from 630,000 Yen to 940,000 Yen(Aug.01)

Most Read

1.
MHLW Suggests R...
2.
JPMA President ...
3.
Chugai Half-Yea...
4.
Cabinet Approve...
5.
With Series of ...

News Calendar